"With this, Bajaj Healthcare aims to provide a safe and effective treatment option for epilepsy patients in India," the ...

The cost-effectiveness agency has backed Ontozry (cenobamate) as an option for treating focal onset seizures with or without secondary generalised seizures in adults with drug-resistant epilepsy ...

PM, Bajaj Healthcare share price was up 6.2 per cent at Rs 715.6 per share on BSE. In comparison, the BSE Sensex was up 0.3 ...

SK Biopharm and Eurofarma have been partners since June 2022 as the two companies entered a licensing agreement to commercialize SK Biopharm’s anti-seizure drug Cenobamate in Latin America.

Dong-A ST announced on the 20th that it has applied for the approval of SK Biopharm's epilepsy new drug 'cenobamate' from the Ministry of Food and Drug Safety. Dong-A ST signed a technology ...

SEOUL, Jan. 15 (Yonhap) -- SK Biopharmaceuticals Co. (SK Biopharm), a biopharmaceutical arm of SK Group, will establish a joint venture with a major South American biopharma, Eurofarma, in the ...

According to the French Nuclear and Alternative... Dong-A ST seeks domestic approval for SK Biopharm's cenobamate epilepsy drug Dong-A ST announced on the 20th that it has applied for the approval ...

The Company has received recommendation from SEC (Neurology & Psychiatry) of CDSCO to conduct Phase III clinical trials for Cenobamate Tablets ...